Literature DB >> 17452813

From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.

Robert H Young1.   

Abstract

This is the second of a two-part consideration of metastatic tumors to the ovary. Here, the matter is considered in 16 categories, largely site-specific. The first tumor discussed is gastric carcinoma of intestinal-type whose ovarian manifestations have been the subject of a recent paper which emphasized its differences from the Krukenberg tumor. Coverage of intestinal adenocarcinoma emphasizes the landmark 1987 paper of RH Lash and WR Hart. The section on pancreatic neoplasms reemphasizes the problems caused by metastatic ductal carcinoma, considered primarily in Part I, and discusses less common issues such as spread of neuroendocrine and acinar cell carcinomas. The limited information on spread of tumors of the gallbladder and extrahepatic bile ducts is then reviewed before more detailed consideration of hepatic neoplasms, prompted by recent contributions on hepatocellular carcinoma and intrahepatic cholangiocarcinoma, the latter based on significant experience with this problem in Thailand. The section on appendiceal neoplasms highlights ovarian spread of diverse tumors ranging from typical intestinal-type adenocarcinoma to signet-ring cell carcinomas with various patterns which in the ovary may prompt diagnoses such as a goblet cell (mucinous) carcinoid tumor, but whose ovarian features place them in the category of a Krukenberg tumor. The diverse problems in differential diagnosis of carcinoid tumor (provoked by nested, acinar, and other patterns, including folliclelike spaces) are then reviewed. The section on breast cancer emphasizes that, although usually a manifestation of late stage disease and often not bulky in the ovaries, metastatic breast cancer may form large masses which can represent the clinical presentation. That patients with breast cancer have an increased risk of primary ovarian cancer and that the latter is more common than secondary spread of breast cancer is noted. The section on lung tumors largely reflects information in a recent paper that small cell carcinoma and adenocarcinoma are the lung cancers that spread to the ovary most commonly. The extremely broad differential diagnosis posed by metastatic malignant melanoma ranging from that of an oxyphilic tumor, to a small cell tumor, to a follicle-forming neoplasm, is then considered. The sections on renal cell carcinoma and other urinary tract neoplasms emphasize the differential diagnosis of metastatic clear cell carcinoma and primary clear cell carcinoma, an issue usually resolvable by an awareness of the various features of the ovarian variant, rarely or never seen in the renal variant. The section on metastatic sarcomas discusses endometrial stromal sarcomas, gastrointestinal stromal neoplasms, and miscellaneous other sarcomas. The endometrial stromal tumors are problematic largely because the history of a primary tumor may be remote, in the ovaries the typical growth and vascular pattern of endometrial stromal neoplasms is not always conspicuous, and some endometrial stromal sarcomas in the ovary show sex cordlike patterns of growth. Recent information has indicated that gastrointestinal stromal tumors may rarely have significant ovarian manifestations and if the primary neoplasm is overlooked, the ovarian tumor may be misdiagnosed, usually as an ovarian fibromatous tumor, but potentially as another primary neoplasm. The sections on ovarian spread of uterine carcinomas emphasize the problems owing to cervical adenocarcinomas, which have a greater tendency to involve the ovaries than squamous cell carcinomas and can simulate primary mucinous or endometrioid cancers. The final neoplasms considered are malignant mesothelioma and the desmoplastic small round cell tumor. The microscopic features of malignant mesothelioma are so different from those of primary ovarian carcinoma in most instances that the diagnosis should be readily established on routine microscopic evaluation. The differential diagnosis of the desmoplastic small round cell tumor is more complex because of the greater overlap with the many other small cell malignant tumors that may involve the ovaries primarily or secondarily. Nonetheless, differences exist in most cases and awareness of the entity should lead to consideration of the desmoplastic neoplasm, particularly in a young female. In this area, as in a number of others considered in the review, immunohistochemistry may play a significant, sometimes crucial, role. However, as pointed out in brief concluding remarks, despite the aid of that modality, as in surgical pathology overall, careful consideration of the clinical background, distribution of disease, gross characteristics and spectrum of routine microscopic findings, will lead to the correct diagnosis in the majority of cases and at the very least lead to formulation of a considered differential diagnosis such that use of special techniques may be judicious and those results placed in context of the time-honored clinical and pathologic features.

Entities:  

Mesh:

Year:  2007        PMID: 17452813     DOI: 10.1097/PAP.0b013e3180504abf

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  24 in total

Review 1.  Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting.

Authors:  Antonio González-Martín; Gemma Toledo; Luis Chiva
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

2.  Metastatic ovarian tumor.

Authors:  Sarita Asotra; Jaishree Sharma; Neelam Sharma
Journal:  J Cytol       Date:  2009-10       Impact factor: 1.000

Review 3.  [Morphology of secondary ovarian tumors and metastases].

Authors:  L-C Horn; J Einenkel; R Handzel; A K Höhn
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

4.  Ovarian cancer incidence trends in relation to changing patterns of menopausal hormone therapy use in the United States.

Authors:  Hannah P Yang; William F Anderson; Philip S Rosenberg; Britton Trabert; Gretchen L Gierach; Nicolas Wentzensen; Kathleen A Cronin; Mark E Sherman
Journal:  J Clin Oncol       Date:  2013-05-06       Impact factor: 44.544

Review 5.  Unexpected gynecologic findings during abdominal surgery.

Authors:  Casey A Boyd; Taylor S Riall
Journal:  Curr Probl Surg       Date:  2012-04       Impact factor: 1.909

Review 6.  Gynecologic biopsy for molecular profiling: a review for the interventional radiologist.

Authors:  Bradley R Corr; Kian Behbakht; Monique A Spillman
Journal:  Semin Intervent Radiol       Date:  2013-12       Impact factor: 1.513

7.  The challenge of diagnosing a malignancy metastatic to the ovary: clinicopathological characteristics vary and morphology can be different from that of the corresponding primary tumor.

Authors:  João Lobo; Bianca Machado; Renata Vieira; Carla Bartosch
Journal:  Virchows Arch       Date:  2016-10-18       Impact factor: 4.064

8.  Ovarian Fibrosarcoma: Clinicopathologic Considerations about the Intraoperative and Post-Surgical Procedures.

Authors:  Angel García Jiménez; Josep Castellví; Assumpció Pérez Benavente; Isabela Díaz de Corcuera Frutos; Santiago Ramón Y Cajal
Journal:  Case Rep Med       Date:  2010-02-07

9.  A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer.

Authors:  Jean-Philippe Meyniel; Paul H Cottu; Charles Decraene; Marc-Henri Stern; Jérôme Couturier; Ingrid Lebigot; André Nicolas; Nina Weber; Virginie Fourchotte; Séverine Alran; Audrey Rapinat; David Gentien; Sergio Roman-Roman; Laurent Mignot; Xavier Sastre-Garau
Journal:  BMC Cancer       Date:  2010-05-21       Impact factor: 4.430

10.  [Specialized histopathological second opinion of advanced ovarian cancer. Experiences with collectives from prospective randomized phase III studies].

Authors:  S Kommoss; J Pfisterer; A du Bois; D Schmidt; F Kommoss
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.